ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Want to see AVBP full AI Analyst Report?
Top Page
ArriVent BioPharma, Inc.
(NASDAQ:AVBP)
Select Model
Select Model
Rating:57Neutral
Price Target:
$31.00
▲(4.59% Upside)
Action:Reiterated
Date:05/30/26
The score is held back primarily by pre-revenue status, sizable losses, and meaningful cash burn despite a very strong, low-leverage balance sheet. Technicals are moderately supportive with a clear uptrend across key moving averages, while valuation is constrained by negative earnings and no dividend. A positive corporate update around AACR data provides incremental support but does not outweigh the current lack of revenue and ongoing funding needs.
Positive Factors
Low leverage and strengthened balance sheet
Extremely low debt and a materially expanded asset base provide financial flexibility and lower refinancing risk. This durable strength supports multi‑period R&D spending and late‑stage trials without immediate credit pressure, enabling strategic optionality for partnerships or staged development.
Negative Factors
Pre‑revenue business model
No product revenue leaves long‑term value entirely contingent on successful clinical development and regulatory approval. This structural lack of operating income increases binary outcome risk, lengthens time to self‑sustaining cash generation, and maintains dependence on external funding over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and strengthened balance sheet
Extremely low debt and a materially expanded asset base provide financial flexibility and lower refinancing risk. This durable strength supports multi‑period R&D spending and late‑stage trials without immediate credit pressure, enabling strategic optionality for partnerships or staged development.
Read all positive factors
ArriVent BioPharma, Inc. (AVBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.41B
Dividend YieldN/A
Average Volume (3M)455.62K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue GrowthN/A
EPS Growth6.28%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.53
Shares Outstanding46,574,930
10 Day Avg. Volume515,032
30 Day Avg. Volume455,618
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.91
Forecast
1Y Price Target
$44.56Price Target Upside50.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.96
Revenue Forecast (FY)N/A
ArriVent BioPharma, Inc. Business Overview & Revenue Model
Company Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the develo...
How the Company Makes Money
null...
ArriVent BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -151.31M | -177.53M | -80.49M | -74.59M | 0.00 | -51.61M |
| Net Income | -145.24M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Balance Sheet | ||||||
| Total Assets | 349.30M | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Cash, Cash Equivalents and Short-Term Investments | 326.38M | 312.82M | 218.86M | 150.39M | 163.37M | 37.28M |
| Total Debt | 419.00K | 14.00K | 176.00K | 317.00K | 139.00K | 0.00 |
| Total Liabilities | 25.32M | 25.95M | 17.29M | 11.80M | 8.37M | 1.82M |
| Stockholders Equity | 323.98M | 307.22M | 257.65M | 151.30M | 174.46M | 41.22M |
Cash Flow | ||||||
| Free Cash Flow | -134.47M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Operating Cash Flow | -134.47M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Investing Cash Flow | -104.47M | -71.23M | -192.47M | 0.00 | 0.00 | -40.00M |
| Financing Cash Flow | 251.18M | 203.06M | 186.58M | 42.86M | 169.72M | 89.87M |
ArriVent BioPharma, Inc. Technical Analysis
Positive
29.64
Price Trends
27.28
Positive
25.02
Positive
22.59
Positive
Market Momentum
-0.06
Positive
60.73
Neutral
58.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Positive. The current price of 29.64 is above the 20-day moving average (MA) of 28.41, above the 50-day MA of 27.28, and above the 200-day MA of 22.59, indicating a bullish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 60.73 is Neutral, neither overbought nor oversold. The STOCH value of 58.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVBP.
ArriVent BioPharma, Inc. Risk Analysis
ArriVent BioPharma, Inc. disclosed 92 risk factors in its most recent earnings report. ArriVent BioPharma, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ArriVent BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.69B | -16.57 | -56.07% | ― | 3.42% | -11.04% | |
57 Neutral | $1.41B | -9.39 | -48.98% | ― | ― | 6.28% | |
53 Neutral | $1.83B | -4.85 | -50.17% | ― | 34.26% | 23.00% | |
52 Neutral | $1.78B | -8.57 | -145.81% | ― | -10.44% | 19.99% | |
52 Neutral | $2.69B | -9.27 | -43.94% | ― | 39.04% | 29.88% | |
52 Neutral | $1.04B | -7.71 | 1870.38% | ― | -50.80% | 14.80% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
AVBP
ArriVent BioPharma, Inc.
30.27
8.27
37.59%
QURE
uniQure
28.53
14.05
96.96%
IOVA
Iovance Biotherapeutics
4.10
2.34
132.95%
RLAY
Relay Therapeutics
14.05
10.87
341.82%
IVA
Inventiva
4.93
1.54
45.43%
TSHA
Taysha Gene Therapies
5.87
3.09
111.15%
ArriVent BioPharma, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
ArriVent BioPharma Updates At-The-Market Equity Offering Program
Neutral
May 11, 2026
On May 11, 2026, ArriVent BioPharma, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to update its existing at-the-market equity offering program. Under this supplement, the company may, from time to time, sell ...
Business Operations and StrategyProduct-Related Announcements
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
Positive
Mar 17, 2026
On March 17, 2026, ArriVent BioPharma announced it would present new preclinical data on its EGFR inhibitor firmonertinib and dual-target MUC16/NaPi2b tetravalent ADC ARR-002 at the 2026 American Association for Cancer Research Annual Meeting in S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.